| Literature DB >> 21876809 |
Ana-Maria Enciu1, Stefan N Constantinescu, Laurenţiu M Popescu, Dafin F Mureşanu, Bogdan O Popescu.
Abstract
Vascular dementia is, in its current conceptual form, a distinct type of dementia with a spectrum of specific clinical and pathophysiological features. However, in a very large majority of cases, these alterations occur in an already aged brain, characterized by a milieu of cellular and molecular events common for different neurodegenerative diseases. The cell signaling defects and molecular dyshomeostasis might lead to neuronal malfunction prior to the death of neurons and the alteration of neuronal networks. In the present paper, we explore some of the molecular mechanisms underlying brain malfunction triggered by cerebrovascular disease and risk factors. We suggest that, in the age of genetic investigation and molecular diagnosis, the concept of vascular dementia needs a new approach.Entities:
Year: 2011 PMID: 21876809 PMCID: PMC3160011 DOI: 10.4061/2011/401604
Source DB: PubMed Journal: J Aging Res ISSN: 2090-2204
Figure 1Evolution throughout time of vascular dementia concept.
Figure 2Some mechanisms converging towards neuronal malfunction in two major types of dementia.
Comparison between normal aging and neurodegenerative diseases from a molecular perspective.
| Parameter | Normal aging | Vascular dementia | Alzheimer's disease | Other neurodegenerative disorders |
|---|---|---|---|---|
| CBF | Diminished with lower velocity, but with preserved dynamic adaptability [ | Diminished in parietal and frontal lobes, some authors reported also a decrement in superior temporal gyri, thalami, anterior cingulate gyri [ | Diminished only in parietal cortices and later in advanced disease in frontal lobes [ | Diminished in preoccipital and occipital regions in PD [ |
|
| ||||
| VEGF -A | Low basal levels produced by astrocytes [ | Upregulation of VEGF and VEGF R2 in astrocytes [ | Low serum levels and decreased secretion by peripheral immune cells [ | FTLD—associated with VEGF gene promoter polymorphism in selected populations [ |
|
| ||||
| Inflammatory cytokines | ||||
| IL-6 | Increased mRNA compared to young subjects [ | High blood levels, associated with high CRP may be associated with high risk [ | Positive immunoreactivity in amyloid plaques and increased concentration in AD brain, compared to age-matched subjects [ | Increased in cerebral and cerebellar cortex of Huntington patients [ |
| TNF | Increased basal levels in aged laboratory animals with week induction injury response [ | Modulates neuronal cell loss in cerebral ischemia [ | Increased expression in AD brain, along with TNF-R1 [ | Increased in plasma [ |
| TGF | Detected at low levels in CSF and produced in CNS at low levels by neuronal cells [ | Increased in CNS and CSF after stroke [ | Increased in areas with amyloid burden [ | CAA—directly related to amyloid vascular deposition [ |
|
| ||||
| Adhesion molecules | sVCAM increased [ | sVCAM increased in atherosclerotic disease [ | sVCAM elevated in late onset AD [ | sVCAM increased in Down Syndrome [ |
|
| ||||
| ROS | Increased accumulation with aging [ | Increased in ischemia animal models and stroke patients [ | Increased: A | Increased in PD |
|
| ||||
| Lipid metabolism | Accumulation of ceramides and free cholesterol in cerebral cortex [ | Hypercholesterolemia is a known risk factor for VaD | Increased levels of cholesterol, and activation of cholesterol biosynthesis pathway [ | PD dementia does not correlate with apoE polymorphism or lipid profile [ |
| GLUT 1 | Altered structure and function of GLUT-1 [ | Downregulated in prolonged hypoxia [ | Low expression in AD hippocampus and double transgenic APP/PS1 animal model Learning increases expression in mouse brain [ | Insufficiently investigated in neurodegeneration, but involved in “Glut-1 deficiency syndrome”— a treatment-resistant form of epilepsy [ |
|
| ||||
| BDNF | Decreased mRNA in human plasma and hippocampus [ | Increased expression following hypoxic stress in cell cultures [ | Decreased expression in hippocampus temporal and frontal cortex [ | Reduced BDNF expression in the caudate and putamen in HD patients [ |
|
| ||||
| Calcium | Reduced homeostatic reserve [ | Involved in ischemia-induced excitotoxicity [ | A | Excitotoxicity and excessive Ca2+-mediated nitric oxide production are believed to contribute to the death of dopaminergic neurons in PD [ |
MAOS: membrane-associated oxidative stress VDCC: voltage dependent calcium channels, FTLD: frontotemporal lobar dementia, LBD: Lewy body dementia, and HD: Huntington disease.